Automated Insulin Delivery Devices Market Product Type (Pens, Insulin Pumps, Pen Needles, and Others), By Application (Type-1 Diabetes, Type-2 Diabetes), By End-Use ( Homecare, Hospitals, Clinics) and by Region and Companies Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2022-2032.

Automated Insulin Delivery Devices Market Overview:

The Automated Insulin Delivery Devices Market is projected to reach a valuation of USD 28.87 billion by 2032 at a CAGR of 7.9%, from USD 12.51 billion in 2021.

An automated insulin delivery system, also known as a hybrid closed loop insulin delivery system is used to keep blood glucose levels stable and prevent hypoglycemia.

Automated insulin delivery systems are computer-controlled (or semi-automated) systems that enable patients with diabetes, mainly Type-1, to control their blood glucose levels by automatically altering insulin delivery.

Currently available systems can only supply (and regulate) a single hormone: insulin. Other systems in development aim to improve on present systems by adding one or more hormones that can be supplied as needed, facilitating the endocrine capabilities of a healthy pancreas.

An automated insulin delivery system has three parts: a Continuous Glucose Monitor (CGM) to determine blood sugar levels, a pump to inject insulin, and an algorithm to transmit commands to the pump based on data from the CGM.

Detailed Segmentation

Based on Product Type:

• Pens
• Insulin Pumps
• Pen Needles
• Insulin Syringes
• Other Product Types

Based on Application:

• Type-1 Diabetes
• Type-2 Diabetes

Based on End-Use:

• Homecare
• Hospitals
• Clinics

Based on Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Market Dynamics

Drivers for the Global Automated Insulin Delivery Devices Market:

The surge in diabetes incidence around the globe is likely to fuel market growth for the automated insulin delivery devices industry. Furthermore, the market for automated insulin delivery devices is expected to increase due to introductions in product innovation.

Furthermore, technical advancements in insulin delivery devices are expected to support the economic growth of the automated insulin delivery devices market.

Restraints Global Automated Insulin Delivery Devices Market:

Oral insulin as a substitute drug delivery process is expected to stymie the expansion of the automated insulin administration systems market. The reuse of pen needles and infusion sets may also pose a threat to the automated insulin delivery device market’s revenue growth trajectory.

Opportunities for the Global Automated Insulin Delivery Devices Market:

The increase in awareness programs and reimbursement scenarios in advanced nations is expected to create additional opportunities for the automated insulin delivery device market to flourish.

Trends for the Global Automated Insulin Delivery Devices Market:

An ever-increasing global diabetic population has prompted commercial and public entities to invest more in diabetes research. In 2019, the National Institutes of Health (NIH) partnered with four institutions to assist in the development of closed-loop insulin administration technology, also known as Automated Insulin Delivery Systems, for pregnant women with Type-1 diabetes.

Competitive Landscape

• Eli Lilly and Company
• Biocon Limited
• WOCKHARDT
• Abbott
• Companion Medical
• F. Hoffmann-La Roche Ltd.
• Becton, Dickinson, and Company
• Medtronic
• Tandem Diabetes Care Inc.
• Novo Nordisk A/S

Recent Developments of Major Players

• In October 2019, Novo Nordisk received FDA approval for the expanded use of its Fiasp insulin infusion pumps in individuals with Type-1 or Type-2 diabetes to improve glycemic control.
• In February 2020, Becton, Dickinson, and Company completed a clinical trial of its BD Libertas wearable injector.

For the XXXXX Market research study, the following years have been considered to estimate the market size: